đź’¨ Abstract
US President Donald Trump's threat of reciprocal import tariffs on Indian pharmaceutical products has caused concern among drugmakers in India, as they export $9 billion worth of drugs and vaccines annually to the US. Indian pharma companies are reviewing their business strategies to absorb the duty shock and are lobbying for a complete duty waiver on drugs coming from the US.
Courtesy: theprint.in
Summarized by Einstein Beta 🤖
Suggested
World's glaciers are losing record ice as global temperatures climb, U.N. says
Oil set for weekly gain on Iran sanctions, OPEC+ plan to rein in overproduction
US, Venezuela trade barbs over migrant deportation flights
Netanyahu government approves firing of Shin Bet head amid protests
Meta's Instagram outage in US nearly resolved as reports drop, Downdetector shows
By opposing farmers’ stir, AAP is playing to the crowd in urban Punjab. But it’s a slippery slope
Pak Army captain, 10 terrorists killed in operation in Khyber Pakhtunkhwa
Jaishankar, Bolivia's foreign minister discusses bilateral ties, signs Quick Impact Projects agreement
Jaishankar meets Commonwealth Secretary General-elect, discusses India's expectations
Delhi: US Embassy files FIR against fake Visa and Passport agents, Crime Branch begins probe
Powered by MessengerX.io